Author details

Full Name

Pierre Laurent-Puig

Affiliation

ORCID

Career Start Year

1986

Papers

508

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37492227	Formyl peptide receptor-1 (FPR1) represses intestinal oncogenesis.		2023
37758611	Features of colorectal adenomas among young patients with Lynch syndrome according to path_MMR: Results from the PRED-IdF registry.		2023
37647991	Molecular-based targeted therapies in patients with hepatocellular carcinoma and hepato-cholangiocarcinoma refractory to atezolizumab/bevacizumab.		2023
37797388	Time to recurrence and its relation to survival after recurrence in patients resected for stage III colon cancer.		2023
37788410	International Validation of the Immunoscore Biopsy in Patients With Rectal Cancer Managed by a Watch-and-Wait Strategy.		2023
38065990	Circadian rhythm and circulating cell-free DNA release on healthy subjects.		2023
37619846	Different prognostic values of KRAS exon 2 submutations and BRAF V600E mutation in microsatellite stable (MSS) and unstable (MSI) stage III colon cancer: an ACCENT/IDEA pooled analysis of seven trials.	Ann Oncol	2023
37686695	Primary Colorectal Tumor Displays Differential Genomic Expression Profiles Associated with Hepatic and Peritoneal Metastases.		2023
37344100	New hormone receptor-positive breast cancer mouse cell line mimicking the immune microenvironment of anti-PD-1 resistant mammary carcinoma.	J Immunother Cancer	2023
37088804	Lynch syndrome: influence of additional susceptibility variants on cancer risk.		2023
36831626	The Position of Circulating Tumor DNA in the Clinical Management of Colorectal Cancer.		2023
37142595	Intratumor heterogeneity and cell secretome promote chemotherapy resistance and progression of colorectal cancer.		2023
36759241	Adenoid cystic carcinoma of Bartholin's gland, a case report with genomic data and literature review.		2023
37390800	Circulating tumour DNA at baseline for individualised prognostication in patients with chemotherapy-naÃ¯ve metastatic colorectal cancer. An AGEO prospective study.		2023
37263081	The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022.		2023
36695651	A novel VCP::TFE3 gene fusion resulting from t(X;9)(p11.23;p13.3) chromosome translocation in TFE3 rearranged renal cancer cell carcinoma.		2023
37189151	A novel Chr1-miR-200 driven whole transcriptome signature shapes tumor immune microenvironment and predicts relapse in early-stage lung adenocarcinoma.		2023
36804053	Ipilimumab with atezolizumab-bevacizumab in patients with advanced hepatocellular carcinoma: The PRODIGE 81-FFCD 2101-TRIPLET-HCC trial.	Dig Liver Dis	2023
37439810	Transcriptomic Signatures of MSI-High Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors.		2023
36848605	Olaparib in the Setting of Radiotherapy-Associated Sarcoma: What Can Precision Medicine Offer For Rare Cancers?		2023
37535388	Avelumab vs Standard Second-Line Chemotherapy in Patients With Metastatic Colorectal Cancer and Microsatellite Instability: A Randomized Clinical Trial.		2023
37533102	Downregulation of mitochondrial complex I induces ROS production in colorectal cancer subtypes that differently controls migration.		2023
35323926	Highly Specific Droplet-Digital PCR Detection of Universally Methylated Circulating Tumor DNA in Endometrial Carcinoma.	Clinical Chemistry	2022
35962130	A proof of concept for targeting the PrP - Amyloid Î² peptide interaction in basal prostate cancer and mesenchymal colon cancer.	Oncogene	2022
35643579	Potential competing risk of death in older high-risk endometrial carcinoma patients: Results from a multicentric retrospective cohort.	Gynecologic Oncology	2022
35752712	Discovery and validation of a transcriptional signature identifying homologous recombination-deficient breast, endometrial and ovarian cancers.	British Journal of Cancer	2022
35565398	Epidemiology, Risk Factors and Diagnosis of Small Bowel Adenocarcinoma.	Cancers	2022
35610167	FFCD 1709-SIRTCI phase II trial: Selective internal radiation therapy plus Xelox, Bevacizumab and Atezolizumab in liver-dominant metastatic colorectal cancer.	Dig Liver Dis	2022
35351371	SOCRATE-PRODIGE 55 trial: A randomized phase II study to evaluate second-line ramucirumab alone or with paclitaxel in older patients with advanced gastric cancer.	Digestive and Liver Disease	2022
34801228	[Place of PARP inhibitors in the treatment of endometrial and cervical cancers].		2022
34732839	Stratification of chemotherapy-treated stage III colorectal cancer patients using multiplexed imaging and single-cell analysis of T-cell populations.	Mod Pathol	2022
35033379	Development and validation of a RNAseq signature for prognostic stratification in endometrial cancer.	Gynecologic Oncology	2022
35231421	Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer.	Immunity	2022
35151910	BRCA1 and RAD51C promotor methylation in human resectable pancreatic adenocarcinoma.	Clinics and Research in Hepatology and Gastroenterology	2022
34894121	Circulating Ubiquitous RNA, A Highly Predictive and Prognostic Biomarker in Hospitalized Coronavirus Disease 2019 (COVID-19) Patients.	Clinical Infectious Diseases	2022
34601553	FLINO: a new method for immunofluorescence bioimage normalization.	Bioinformatics	2022
34811505	Prognostic value of circulating tumour DNA in metastatic pancreatic cancer patients: post-hoc analyses of two clinical trials.	British Journal of Cancer	2022
34754079	An atlas of inter- and intra-tumor heterogeneity of apoptosis competency in colorectal cancer tissue at single-cell resolution.	Cell Death Differ	2022
35120842	Circulating tumor DNA: a help to guide therapeutic strategy in patients with borderline and locally advanced pancreatic adenocarcinoma?	Digestive and Liver Disease	2022
34638228	Role of Circulating Tumor DNA in Gastrointestinal Cancers: Current Knowledge and Perspectives.	Cancers	2021
33489470	A major genetic accelerator of cancer diagnosis: rs867228 in FPR1.	OncoImmunology	2021
34016488	Circulating tumor DNA in advanced non-small-cell lung cancer patients with HIV is associated with shorter overall survival: Results from a Phase II trial (IFCT-1001 CHIVA).	Lung Cancer	2021
33747362	Fine-mapping of two differentiated thyroid carcinoma susceptibility loci at 2q35 and 8p12 in Europeans, Melanesians and Polynesians.	Oncotarget	2021
34168047	Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer.	Clinical Cancer Research	2021
33903625	Gene network and biological pathways associated with susceptibility to differentiated thyroid carcinoma.	Scientific Reports	2021
33741693	Deciphering the Role of Intestinal Crypt Cell Populations in Resistance to Chemotherapy.	Cancer Res	2021
33527407	Multiethnic genome-wide association study of differentiated thyroid cancer in the EPITHYR consortium.	Int J Cancer	2021
33785445	Practices and expectations on the use of circulating tumor DNA in colorectal cancer patients: A bi-national AGEO/AIOM/GERCOR/FFCD/FRENCH survey.	Clinics and Research in Hepatology and Gastroenterology	2021
34215534	Pembrolizumab with Capox Bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: The FFCD 1703-POCHI trial.	Dig Liver Dis	2021
33827984	Role of DNA Repair Variants and Diagnostic Radiology Exams in Differentiated Thyroid Cancer Risk: A Pooled Analysis of Two Case-Control Studies.	Cancer Epidemiology Biomarkers and Prevention	2021